Founder of Toms Shoes Pledges $100 Million Towards Psychedelic Research
Toms Shoes founder promises $100 million towards psychedelic research and access.
Founder of Toms Shoes, Blake Mycoskie, pledged to provide $100 million to assist access and research regarding psychedelics (1).
Mycoskie interviewed with MartketWatch (2), where he discussed how the money being donated will aid research, nonprofits working to expand access for patients in need of psychedelic treatments, and support academic institutions researching psychedelic medicine.
Mycoskie shared an experience he had with ayahuasca in 2017. During this psychedelic therapy encounter, he was able to witness healing on another level. “[It] “cracked me open, and it connected me more to my faith in God, made me feel that we were all connected and everything was fine and perfect…I came back just feeling like, wow, that was more powerful than any therapy I’d ever done,” Mycoskie said (1).
The $100 million donation, approximately a quarter of Mycoskie’s net worth, may be the most generous donation to psychedelics research. Blake Mycoskie discussed with MarketWatch (2), ”We really need to get this right, and we really need to have these foundations and nonprofits funded properly … I felt a real sense of urgency.”
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
A Call for More Representative Horticultural Lighting Metrics for Cannabis Cultivation
March 5th 2025This article explores fundamental principles of photobiology, including Photosynthetically Active Radiation, photoreceptor-mediated responses, and the spectral influences on plant morphology and development.
